Login to your account
Don’t have an account?
Create a Free AccountEditor's Choice Archive
Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis
Venous thromboembolic disease is considered one of the leading causes of morbi-mortality [1,2]. in oncological patients. Cancer multiplies the risk of thromboembolic events 6- or 7-fold compared to the general population without cancer [3,4], and this risk is greater in certain tumor sites and in people receiving chemotherapy. The incidence of VTE in individuals with pancreatic cancer is high, although it varies widely in the literature [5–23] due, in part, to the differences in the populations studied.Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitisSpirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases
We propose that spirometry, a practical and validated marker of respiratory function, is also an overlooked marker of global human health throughout a person’s life span, from infancy to old age, because it not only relates to respiratory diseases, but it also identifies individuals at risk of suffering other prevalent chronic non-communicable diseases (NCDs), particularly cardiovascular and metabolic disorders. Accordingly, we propose that spirometry be performed in infancy, adolescence, early and late adulthood.The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues
β-blockers represent a mainstay in the pharmacological approach to patients affected by heart failure with reduced ejection fraction (HFrEF). However, underuse of this class of drugs is still reported, especially in the presence of cardiovascular and non-cardiovascular comorbidities, even if they are not contraindications for prescription of a β-blocker. The prognostic benefit of β-blockers is relevant in the presence of comorbidities, and achievement of the maximum tolerated dose is an important goal to increase their favorable prognostic role.Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) or Rendu–Osler–Weber syndrome (ORPHA774) is a rare autosomal dominant vascular disease characterized by telangiectases and larger vascular malformations (VMs) of the pulmonary, cerebral, or hepatic vasculature [1]. The hallmark of HHT is telangiectasis, which is an abnormal communication between an arteriole and a dilated and tortuous venule in the capillary bed. HHT can be diagnosed either through molecular genetic test or using the Curaçao clinical criteria (recurrent epistaxis, cutaneous/mucosal telangiectasia, visceral VMs, and a first-degree family member with HHT) [2,3].Autologous fecal microbiota transplantation can retain the metabolic achievements of dietary interventions
We recently reported that autologous fecal microbiota transplantation (aFMT), derived from the time of maximal weight-loss and administrated in the regain-phase, might preserve weight loss and glycemic control in moderately obese subjects, and is associated with specific microbiome signatures. Here, we sought to explore the global effect of aFMT on adipokines, inflammatory markers and blood cholesterol and on the overall gut microbiome preservation.Sustainable and personalized nutrition: From earth health to public health
In the difficult times amidst the SARS-CoV-2 pandemic, the whole world has become more conscious of the importance of primary and secondary prevention. COVID-19 is already having a triple hit on health, education and income, but at the same time this scourge offers tremendous opportunities for reaching the 2030 Agenda and the Sustainable Development Goals. In the frame of the pandemic, the planet gave us the strongest warning that the mankind must change in order to prevent the ongoing worldwide degradation of the ecosystem.Sweet taste and obesity
Obesity is associated with significant morbidity and mortality, and currently represents a global health challenge[1]. While it is associated with complex pathophysiology, increased availability of highly palatable foods and beverages, namely those rich in sugar or fat, is thought to be a major determinant of increasing rates of obesity worldwide[2]. Indeed, individuals with obesity have been shown to have altered sensitivity to food reward[3], which is thought to be related to changes in reward-related brain neurocircuitry, namely decreased striatal availability of dopamine D2 receptors (D2R)[3].Patient motivation to lose weight: Importance of healthcare professional support, goals and self-efficacy
Obesity is a global health concern [1]. Multiple complications are associated with overweight and obesity including diabetes, heart disease, musculoskeletal disorders and some cancers, and people with obesity (PwO) are at an increased risk of disability and suffer social stigma [2-5]. In the current time, the risk that obesity poses has been highlighted; it increases the risk for serious complications from viral infections, and in particular is associated with high mortality risk of COVID-19 and H1N1 infections [6-9].The 3Ds – Discussion, diagnosis and direction: Elements for effective obesity care by healthcare professionals
Obesity is a chronic disease associated with multiple health complications [1]. Furthermore, the COVID-19 pandemic has made evident the impact obesity can have on health outcomes, whereby people with obesity (PwO) are more likely to require hospitalisation, require mechanical ventilation and suffer serious complications from the infection than those without obesity [2-6]. As a multifactorial disease, successful weight management requires multidisciplinary care [7-9]. In practice, the care received by PwO is frequently suboptimal, owing to differing perceptions about obesity of healthcare professionals (HCPs) and patients, and clinical barriers such as unavailability or cost of certain treatments and services, and time pressures faced by HCPs [10, 11].How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity
On November 18th 2020, there have been over 55 million confirmed cases of SARS-CoV-2 infection causing COVID-19, with up to 1.3 million deaths worldwide. In the Netherlands alone, there are up to 8,600 registered deaths, a number that is still on the rise. The risk of hospitalization and death increases with age,1-3 illustrated by a case fatality rate increase from a 2.3% in the general population, to 14.8% in patients over 80 years old.4 A contact survey study from Wuhan and Shanghai found the highest susceptibility to infection in individuals older than 65 year.Seventeen-year trend (2001–2017) in pacemaker and implantable cardioverter-defibrillator utilization based on hospital discharge database data: An analysis by age groups
National Registries are needed to monitor health care interventions, optimize the resources and utilize them appropriately [1], but are challenging to implement and manage due to the possible lack and/or inadequacy of data. Moreover, considerable human commitment and substantial economic resources are required to ensure high-quality data collection [2]. Currently, participation in Registries is still mainly voluntary, while to achieve comprehensive data, it should be mandatory and ruled at a national level [3].A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with cancer [1]. Both pathologies interrelate at a deep biological level with numerous interactions between key elements of the hemostatic system and cancer cell programs [2]. Cancer-associated thrombosis (CAT) falls within a panorama of growing complexity in oncology, with the appearance of new anticoagulant therapies, emerging molecular data [3], and new antineoplastic treatments associated with thrombotic risk.Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life
Chronic obstructive pulmonary disease (COPD) was the third leading cause of mortality in 2016 and was responsible for an estimated 3 million deaths worldwide that year, representing a vast global problem [1]. COPD exacerbations are responsible for the majority of the substantial burden that COPD places on healthcare systems [2,3]. In the USA, the annual cost of COPD management has been shown to increase proportionally with the number of COPD exacerbations, with COPD-related costs, including pharmacy claims for COPD treatments, more than six times higher in patients experiencing frequent (≥2/year) exacerbations ($4361) compared with those who had none ($644) [4].
The content on this site is intended for healthcare professionals.
Copyright © 2023 Elsevier Inc. except certain content provided by third parties.
